A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T77478 | Milatuzumab | 899796-83-9 | 98% |
Milatuzumab
|
Milatuzumab (MEDI-115) is a humanized monoclonal antibody against CD74. Milatuzumab promotes the production of free radical oxygen and the loss of mitochondrial ... | ||||
T77480 | Bivatuzumab | 214559-60-1 | 98% |
Bivatuzumab
|
Bivatuzumab (BIWA 4) is a humanized monoclonal antibody against CD44v6. | ||||
T77484 | Atibuclimab | 2417175-94-9 | 98% |
Atibuclimab
|
Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat ... | ||||
T77491 | Prezalumab | 1523164-68-2 | 98% |
Prezalumab
|
Prezalumab (AMG 557) is a human IgG2 monoclonal antibody against ICOSL and BAFF. Prezalumab can be used to study sjogren's syndrome cutaneous lupus erythematosus... | ||||
T77493 | Murlentamab | 2058047-65-5 | 98% |
Murlentamab
|
Murlentamab (GM102) is a humanized anti-AMhRII antibody. Murlentama has potential antitumor activity that induces macrophage-mediated antitumor-dependent cell-me... | ||||
T10497 | Benralizumab | 1044511-01-4 | 98% |
|
Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, ... | ||||
T9904 | Bevacizumab | 216974-75-3 | 98% |
|
Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A. | ||||
T9928 | Ranibizumab | 347396-82-1 | 98% |
|
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and... | ||||
T38951 | Isatuximab | 1461640-62-9 | 98% |
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system and is a hi... | ||||
T9925 | Ofatumumab | 679818-59-8 | 98% |
Ofatumumab
|
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation | ||||
T35391 | Vibostolimab (anti-TIGIT) | 2231305-30-7 | 98% |
Vibostolimab (anti-TIGIT)
|
Vibostolimab is a monoclonal antibody against T cell immune proteins and the ITIM domain.Vibostolimab has shown anti-tumor activity in in vitro trials and can be... | ||||
T39057 | Rozanolixizumab | 1584645-37-3 | 98% |
|
Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pa... | ||||
T9962 | Mepolizumab | 196078-29-2 | 98% |
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody neutralizing IL-5. Mepolizumab can be used in studies about severe eosinophilic asthma and eosinophili... |